Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
AdvanTIG-203
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positivity (TAP) ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
3 other identifiers
interventional
125
6 countries
86
Brief Summary
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Mar 2021
86 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 25, 2021
CompletedFirst Posted
Study publicly available on registry
February 1, 2021
CompletedStudy Start
First participant enrolled
March 31, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 26, 2023
CompletedResults Posted
Study results publicly available
January 31, 2025
CompletedJanuary 31, 2025
December 1, 2024
1.8 years
January 25, 2021
December 23, 2024
December 23, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Objective Response Rate (ORR) Assessed by the Investigator
Objective response rate is defined as the percentage of participants who had a best overall response of confirmed complete response (CR) or partial response (PR) assessed by the Investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Response evaluations were performed using computed tomography or magnetic resonance imaging (MRI) approximately every 6 weeks for the first 54 weeks and then every 12 weeks thereafter. CR: Disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) \< 10 mm, and no new lesions. PR: At least a 30% decrease in the size of target lesions, with no progression of non-target lesions and no new lesions, or disappearance of target lesions with persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, and no new lesions. Response (CR or PR) must have been confirmed 4 weeks or later after the first response was observed.
Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.
Secondary Outcomes (11)
Overall Survival
From randomization to the end of the study, median (range) time on follow-up was 10.0 (0.5 - 29.9) months in Arm A and 7.8 (0.4 - 29.3) months in Arm B.
Objective Response Rate Assessed by the Independent Review Committee
Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.
Progression-free Survival (PFS) Assessed by the Independent Review Committee
From randomization up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.
Progression-free Survival (PFS) Assessed by the Investigator
From randomization to the end of the study, median (range) time on follow-up was 10.0 (0.5 - 29.9) months in Arm A and 7.8 (0.4 - 29.3) months in Arm B.
Duration Of Response (DOR) Assessed by the Independent Review Committee
From randomization up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.
- +6 more secondary outcomes
Study Arms (2)
Arm A: Tislelizumab plus Ociperlimab
EXPERIMENTALParticipants received 200 milligrams (mg) tislelizumab plus 900 mg ociperlimab intravenously once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.
Arm B: Tislelizumab plus Placebo
PLACEBO COMPARATORParticipants received 200 mg tislelizumab plus placebo intravenously once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.
Interventions
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
Eligibility Criteria
You may qualify if:
- Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC).
- Have progressive disease during or after first-line of systemic treatment for unresectable, locally advanced, recurrent or metastatic ESCC.
- Have measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Have confirmed programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% in tumor tissues tested by the central lab.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
You may not qualify if:
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
- Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta).
- Evidence of complete esophageal obstruction not amenable to treatment.
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks after intervention).
- Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc) or any investigational therapies within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug. Or has received palliative radiation treatment or other local regional therapies within 14 days before the first dose of study drug.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- BeiGenelead
Study Sites (86)
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230088, China
Quanzhou First Hospital of Fujian Province
Quanzhou, Fujian, 362002, China
First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
Lanzhou University Second Hospital
Gansu, Gansu, China
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Meizhou Hospital Affiliated to Sun Yat-sen University
Guangzhou, Guangdong, China
Hainan Third People's Hospital
Sanya, Hainan, China
Nantong Tumor Hospital
Nantong, Jiangsu, 226000, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Qinghai Provincial People's Hospital
Qinghai, Qinghai, China
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, 140100, China
People's Hospital of Deyang City
Deyang, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
First Affiliated Hospital of Kunming Medical University
Yunnan, Yunnan, China
Beijing Cancer Hospital
Beijing, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, 046000, China
The First People's Hospital of Changzhou
Changzhou, China
Fujian Cancer Hospital
Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fujian, China
Zhongshan Hospital Xiamen University
Fujian, China
Cancer Hospital of Shantou University Medical College
Guangdong, China
Nanfang Hospital of Southern Medical University
Guangdong, China
Sun Yat-sen University Cancer Center
Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangdong, China
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Guangxi, China
Hainan General Hospital
Hainan, China
Affiliated Hospital of Hebei University
Hebei, China
The Second Hospital of Anhui Medical University
Hefei, China
Harbin Medical University Cancer Hospital
Heilongjiang, China
Henan Cancer Hospital
Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Henan, China
The First Affiliated Hospital of Zhengzhou University
Henan, China
Hubei Cancer Hospital
Hubei, China
Xiangyang Central Hospital
Hubei, China
Hunan Cancer Hospital
Hunan, China
The First Affiliated Hospital of Nanchang University
Jiangxi, China
The Second Affiliated Hospital of Nanchang University
Jiangxi, China
Linyi Cancer Hospital
Shandong, China
Weifang People's Hospital
Shandong, China
Shanghai Chest Hospital
Shanghai, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Sichuan Provincial People's Hospital
Sichuan, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Northern Jiangsu People's Hospital
Yangzhou, China
Hangzhou Cancer Hospital
Zhejiang, China
Hwa Mei Hospital, University of Chinese Academy of Sciences
Zhejiang, China
Centre Hospitalier Universitaire d'Amiens - Hopital Sud
Amiens, Picardie, France
Hôpital de la Timone
Marseille, France
Hopital Europeen Georges Pompidou - Digestive Oncology
Paris, 75015, France
CHU de Poitiers
Poitiers, 80621, France
Ajou University Hospital
Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital
Jeongnam, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Institut Catala D'Oncologia
L'Hospitalet de Llobregat, Spain
Hospital Universitario Madrid Sanchinarro
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Regional Universitario de Málaga
Málaga, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Clinico Universitario de Valencia - Incliva
Valencia, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Chiayi Chang Gung Memorial Hospital
Chiayi City, Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan
Chulabhorn Hospital
Bangkok, Thailand
Phramongkutklao Hospital
Bangkok, Thailand
Rajavithi Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University
Chiang Mai, Thailand
Songklanagarind Hospital, Prince of Songkla University
Hat Yai, Thailand
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Study Director
- Organization
- BeiGene, Ltd.
Study Officials
- STUDY DIRECTOR
Study Director
BeiGene
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 25, 2021
First Posted
February 1, 2021
Study Start
March 31, 2021
Primary Completion
February 1, 2023
Study Completion
December 26, 2023
Last Updated
January 31, 2025
Results First Posted
January 31, 2025
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will share